In medicine today – Cancer and the prorogation of clinical reality in favour of probabilistic outcomes

[1] Wechsler LR. Statins and Stroke - It’s Complicated. N Engl J Med 2020; 382:81–82 WechslerLR Statins and Stroke - It’s Complicated N Engl J Med 2020 382 81 82 Search in Google Scholar

[2] Jolobe Oscar M.P. Titration of antihypertensive therapy to mitigate the risk of falls. LETTERS TO THE EDITOR. Clinical Medicine 2022 Vol 22 No 6:597. DOI 10.7861/clinmed.Let.22.6.1 Jolobe OscarM.P. Titration of antihypertensive therapy to mitigate the risk of falls. LETTERS TO THE EDITOR Clinical Medicine 2022 22 6 597 10.7861/clinmed.Let.22.6.1 Open DOISearch in Google Scholar

[3] Jenei K, Moraes FY, Gyawali B. Globalisation of clinical trials in oncology: a double-edged sword? BMJ Oncology 2023;2:e000163. doi:10.1136/bmjonc-2023-000163 JeneiK MoraesFY GyawaliB Globalisation of clinical trials in oncology: a double-edged sword? BMJ Oncology 2023 2 e000163 10.1136/bmjonc-2023-000163 Open DOISearch in Google Scholar

[4] Kirkwood JM, Strawderman MH, Ernstoff Ms, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7–17. KirkwoodJM StrawdermanMH ErnstoffMs Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 1996 14 7 17 Search in Google Scholar

[5] Williams MV, De Takats P, Parmar M. Survival benefit in melanoma. J Clin Oncol, 1997; 15, No 5 (May), 2172. WilliamsMV De TakatsP ParmarM Survival benefit in melanoma J Clin Oncol 1997 15 5 May 2172 Search in Google Scholar

[6] Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ 2017;359: j4530 http://dx.doi.org/10.1136/bmj.j4530 DavisC NaciH GurpinarE Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13 BMJ 2017 359 j4530 http://dx.doi.org/10.1136/bmj.j4530 Search in Google Scholar

[7] Wise PH. Cancer drugs survival and ethics BMJ 2016;355: i5792 WisePH Cancer drugs survival and ethics BMJ 2016 355 i5792 Search in Google Scholar

[8] Van Oosterom At, Judson Ir, Verweij J, Stroobants S, Dumez H, Donato Di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen Os; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumours: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002 Sep;38 Suppl 5:S83–7. doi: 10.1016/s0959-8049(02)80608-6. PMID: 12528778. Van OosteromAt JudsonIr VerweijJ StroobantsS DumezH Donato Di PaolaE SciotR Van GlabbekeM DimitrijevicS NielsenOs European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumours: a report of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 2002 Sep 38 Suppl 5 S83 7 10.1016/s0959-8049(02)80608-6 12528778 Open DOISearch in Google Scholar

[9] Rigo R, Doherty J, Koczka K, Kong S, Ding Pq, Cheng T, Cheung Wy, Monzon Jg. Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis. Curr Oncol. 2021 Oct 5;28(5):3978–3986. doi: 10.3390/curroncol28050338. RigoR DohertyJ KoczkaK KongS DingPq ChengT CheungWy MonzonJg Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis Curr Oncol 2021 Oct 5 28 5 3978 3986 10.3390/curroncol28050338 Open DOISearch in Google Scholar

[10] Ioannidis JPA, Haidich A-B, Lau J. Any casualties in the clash of randomised and observational evidence? No—recent comparisons have studied selected questions, but we do need more data. BMJ 2001;322:879–80 IoannidisJPA HaidichA-B LauJ Any casualties in the clash of randomised and observational evidence?. No—recent comparisons have studied selected questions, but we do need more data BMJ 2001 322 879 80 Search in Google Scholar

[11] Medical Research Council: Streptomycin treatment of pulmonary tuberculosis. BMJ 1948:769–782, Medical Research Council Streptomycin treatment of pulmonary tuberculosis BMJ 1948 769 782 Search in Google Scholar

[12] Hellman S, Hellman Ds: Of mice but not men: Problems of the randomized clinical trial. N Engl J Med 1991; 324:1585–1589. HellmanS HellmanDs Of mice but not men: Problems of the randomized clinical trial N Engl J Med 1991 324 1585 1589 Search in Google Scholar

[13] Yokota T, Kojima S, Yamauchi H, Hatori M. Evidence-based medicine in Japan. www.thelancet.com 2005; Vol 366 July 9, 122. YokotaT KojimaS YamauchiH HatoriM Evidence-based medicine in Japan www.thelancet.com 2005 366 July 9 122 Search in Google Scholar

[14] WU J. Could evidence-based medicine be a danger to progress? www.thelancet.com 2005; Vol. 366 July 9, 122. WUJ Could evidence-based medicine be a danger to progress? www.thelancet.com 2005 366 July 9 122 Search in Google Scholar